<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/424"/><api:result><api:object category="publication" id="424" last-affected-when="2024-03-17T07:55:33.77+00:00" last-modified-when="2024-03-17T07:55:33.77+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/424" created-when="2010-05-17T13:46:19.687+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-01-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1918446" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1053/ctrv.1999.0126" last-modified-when="2022-09-11T15:59:52.547+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>Alan M</api:first-names><api:separate-first-names><api:first-name>Alan</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>Robert E</api:first-names><api:separate-first-names><api:first-name>Robert</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treatment Reviews</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1053/ctrv.1999.0126</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>11</api:day><api:month>4</api:month><api:year>2019</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="3522778" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0032861160" last-modified-when="2023-11-14T17:48:27.73+00:00"><api:citation-count>36</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes are targets for specific immunotherapy as they are presented in association with human leucocyte antigen class I molecules and are recognised by cytotoxic T lymphocytes. This article reviews the discovery, development, role and therapeutic potential of MAGE tumour-associated antigens. Knowledge in this field of study is in its early stages. Future advances can be anticipated in term of defining therapeutic relevance, antigen detection and discovery of related genes.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35481567300</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448130</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treatment Reviews</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="424" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10448130" last-modified-when="2020-04-29T01:21:45.217+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes are targets for specific immunotherapy as they are presented in association with human leucocyte antigen class I molecules and are recognised by cytotoxic T lymphocytes. This article reviews the discovery, development, role and therapeutic potential of MAGE tumour-associated antigens. Knowledge in this field of study is in its early stages. Future advances can be anticipated in term of defining therapeutic relevance, antigen detection and discovery of related genes.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK.</api:line></api:address></api:addresses></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10448130</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treat Rev</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh">Cancer Vaccines</api:keyword><api:keyword scheme="mesh">Gene Expression</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Melanoma-Specific Antigens</api:keyword><api:keyword scheme="mesh">Multigene Family</api:keyword><api:keyword scheme="mesh">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Netherlands</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0305-7372(99)90126-3</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>21</api:day><api:month>9</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="881825" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10448130" last-modified-when="2022-02-01T18:39:27.127+00:00"><api:citation-count>22</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes are targets for specific immunotherapy as they are presented in association with human leucocyte antigen class I molecules and are recognised by cytotoxic T lymphocytes. This article reviews the discovery, development, role and therapeutic potential of MAGE tumour-associated antigens. Knowledge in this field of study is in its early stages. Future advances can be anticipated in term of defining therapeutic relevance, antigen detection and discovery of related genes.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1967</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448130</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer treatment reviews</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh">Cancer Vaccines</api:keyword><api:keyword scheme="mesh">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Gene Expression</api:keyword><api:keyword scheme="mesh">Multigene Family</api:keyword><api:keyword scheme="mesh">Melanoma-Specific Antigens</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>17</api:day><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="2903695" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1033765900" last-modified-when="2024-03-17T07:55:33.773+00:00"><api:citation-count>30</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>6</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>Alan M</api:first-names><api:separate-first-names><api:first-name>Alan</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0614711555.42</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>Robert E</api:first-names><api:separate-first-names><api:first-name>Robert</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448130</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treatment Reviews</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for-2020">3204 Immunology</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Genetics</api:keyword><api:keyword scheme="rcdc">Immunization</api:keyword><api:keyword scheme="rcdc">Vaccine Related</api:keyword><api:keyword scheme="hrcs-rac">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">5.2 Cellular and gene therapies</api:keyword><api:keyword scheme="hrcs-rac">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh">Cancer Vaccines</api:keyword><api:keyword scheme="mesh">Gene Expression</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Melanoma-Specific Antigens</api:keyword><api:keyword scheme="mesh">Multigene Family</api:keyword><api:keyword scheme="mesh">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.71</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="240523" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000082269900004" last-modified-when="2024-03-14T05:37:03.173+00:00"><api:citation-count>36</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000082269900004&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0126</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0126"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0126"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1967</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">230UZ</api:identifier><api:identifier scheme="pubmed">10448130</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER TREATMENT REVIEWS</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>tumour-associated antigen</api:keyword><api:keyword>MAGE</api:keyword><api:keyword>cancer immunotherapy</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record><api:record format="native" id="23297" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000082269900004" last-modified-when="2014-07-25T11:03:09.42+01:00"><api:citation-count>31</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER TREAT REV</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>tumour-associated antigen</api:keyword><api:keyword>MAGE</api:keyword><api:keyword>cancer immunotherapy</api:keyword><api:keyword>CYTOLYTIC T-LYMPHOCYTES</api:keyword><api:keyword>MAGE GENE FAMILY</api:keyword><api:keyword>SQUAMOUS-CELL-CARCINOMA</api:keyword><api:keyword>TUMOR-REJECTION ANTIGENS</api:keyword><api:keyword>ESOPHAGEAL CARCINOMAS</api:keyword><api:keyword>GASTRIC-CARCINOMA</api:keyword><api:keyword>OCULAR MELANOMA</api:keyword><api:keyword>BREAST-CANCER</api:keyword><api:keyword>PROTEIN</api:keyword><api:keyword>IDENTIFICATION</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>219</api:begin-page><api:end-page>227</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The potential of melanoma antigen expression in cancer therapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>25</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cancer Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Gene Expression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Melanoma-Specific Antigens</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Multigene Family</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cancer Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Gene Expression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Multigene Family</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Melanoma-Specific Antigens</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3204 Immunology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Genetics</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Immunization</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Vaccine Related</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.2 Cellular and gene therapies</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antigens, Neoplasm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cancer Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Gene Expression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Melanoma-Specific Antigens</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Multigene Family</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasm Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasms</api:keyword><api:keyword origin="record-data" source="wos-lite">tumour-associated antigen</api:keyword><api:keyword origin="record-data" source="wos-lite">MAGE</api:keyword><api:keyword origin="record-data" source="wos-lite">cancer immunotherapy</api:keyword><api:keyword origin="record-data" source="wos">tumour-associated antigen</api:keyword><api:keyword origin="record-data" source="wos">MAGE</api:keyword><api:keyword origin="record-data" source="wos">cancer immunotherapy</api:keyword><api:keyword origin="record-data" source="wos">CYTOLYTIC T-LYMPHOCYTES</api:keyword><api:keyword origin="record-data" source="wos">MAGE GENE FAMILY</api:keyword><api:keyword origin="record-data" source="wos">SQUAMOUS-CELL-CARCINOMA</api:keyword><api:keyword origin="record-data" source="wos">TUMOR-REJECTION ANTIGENS</api:keyword><api:keyword origin="record-data" source="wos">ESOPHAGEAL CARCINOMAS</api:keyword><api:keyword origin="record-data" source="wos">GASTRIC-CARCINOMA</api:keyword><api:keyword origin="record-data" source="wos">OCULAR MELANOMA</api:keyword><api:keyword origin="record-data" source="wos">BREAST-CANCER</api:keyword><api:keyword origin="record-data" source="wos">PROTEIN</api:keyword><api:keyword origin="record-data" source="wos">IDENTIFICATION</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0305-7372" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701" title="Cancer Treatment Reviews"><api:records><api:record source-name="summary"><api:title>Cancer Treatment Reviews</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/424/relationships"/></api:object></api:result></api:response>